Rep. Josh Gottheimer Sells Off Shares of Edwards Lifesciences Corporation (NYSE:EW)

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Edwards Lifesciences Corporation (NYSE:EW). In a filing disclosed on December 29th, the Representative disclosed that they had sold between $1,001 and $15,000 in Edwards Lifesciences stock on November 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dassault Systemes (OTCMKTS:DASTY) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of HubSpot (NYSE:HUBS) on 11/19/2025.
• Sold $15,001 – $50,000 in shares of Fidelity National Information Services (NYSE:FIS) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of KKR & Co. Inc. (NYSE:KKR) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 11/19/2025.
• Purchased $1,001 – $15,000 in shares of CSW Industrials (NYSE:CSW) on 11/17/2025.
• Sold $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 10/20/2025.
• Purchased $1,001 – $15,000 in shares of NiCE (NASDAQ:NICE) on 10/17/2025.
• Purchased $1,001 – $15,000 in shares of NetEase (NASDAQ:NTES) on 10/17/2025.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $86.17 on Wednesday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The stock has a market capitalization of $50.01 billion, a P/E ratio of 37.14, a P/E/G ratio of 3.91 and a beta of 0.97. The company’s 50-day moving average is $84.28 and its 200 day moving average is $79.79. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on EW shares. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 29th. BTIG Research reaffirmed a “buy” rating and issued a $103.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Finally, Citigroup restated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $93.95.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $889,000. Randolph Co Inc purchased a new position in Edwards Lifesciences during the 2nd quarter valued at $301,000. OMERS ADMINISTRATION Corp grew its position in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after acquiring an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in Edwards Lifesciences in the second quarter worth $1,760,000. Finally, Arkadios Wealth Advisors purchased a new stake in Edwards Lifesciences in the second quarter worth $300,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,848,828.06. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 45,465 shares of company stock valued at $3,804,610. 0.34% of the stock is currently owned by company insiders.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.